These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
186 related items for PubMed ID: 18173253
21. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease. Vega S, Kang LW, Velazquez-Campoy A, Kiso Y, Amzel LM, Freire E. Proteins; 2004 May 15; 55(3):594-602. PubMed ID: 15103623 [Abstract] [Full Text] [Related]
22. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands. Qiu X, Zhao GD, Tang LQ, Liu ZP. Bioorg Med Chem Lett; 2014 Jun 01; 24(11):2465-8. PubMed ID: 24767846 [Abstract] [Full Text] [Related]
23. Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes. Lu Y, Yang CY, Wang S. J Am Chem Soc; 2006 Sep 13; 128(36):11830-9. PubMed ID: 16953623 [Abstract] [Full Text] [Related]
24. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation. Ghosh AK, Kincaid JF, Walters DE, Chen Y, Chaudhuri NC, Thompson WJ, Culberson C, Fitzgerald PM, Lee HY, McKee SP, Munson PM, Duong TT, Darke PL, Zugay JA, Schleif WA, Axel MG, Lin J, Huff JR. J Med Chem; 1996 Aug 16; 39(17):3278-90. PubMed ID: 8765511 [Abstract] [Full Text] [Related]
25. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. Surleraux DL, de Kock HA, Verschueren WG, Pille GM, Maes LJ, Peeters A, Vendeville S, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB. J Med Chem; 2005 Mar 24; 48(6):1965-73. PubMed ID: 15771440 [Abstract] [Full Text] [Related]
30. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Muzammil S, Ross P, Freire E. Biochemistry; 2003 Jan 28; 42(3):631-8. PubMed ID: 12534275 [Abstract] [Full Text] [Related]
31. Inhibition and catalytic mechanism of HIV-1 aspartic protease. Silva AM, Cachau RE, Sham HL, Erickson JW. J Mol Biol; 1996 Jan 19; 255(2):321-46. PubMed ID: 8551523 [Abstract] [Full Text] [Related]
32. Structure-based ligand design by dynamically assembling molecular building blocks at binding site. Liu H, Duan Z, Luo Q, Shi Y. Proteins; 1999 Sep 01; 36(4):462-70. PubMed ID: 10450088 [Abstract] [Full Text] [Related]
38. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes. da Cunha EF, Sippl W, de Castro Ramalho T, Ceva Antunes OA, de Alencastro RB, Albuquerque MG. Eur J Med Chem; 2009 Nov 22; 44(11):4344-52. PubMed ID: 19616874 [Abstract] [Full Text] [Related]
39. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations. Lepsík M, Kríz Z, Havlas Z. Proteins; 2004 Nov 01; 57(2):279-93. PubMed ID: 15340915 [Abstract] [Full Text] [Related]